Literature DB >> 19517380

Diffusion-weighted MRI of urinary bladder and prostate cancers.

Ozgür Kiliçkesmez1, Tan Cimilli, Ercan Inci, Arda Kayhan, Sibel Bayramoğlu, Neslihan Taşdelen, Nevzat Gürmen.   

Abstract

PURPOSE: The purpose of this study was to evaluate the feasibility of diffusion-weighted imaging in the diagnosis of the urinary bladder and prostate carcinomas. The apparent diffusion coefficient (ADC) values of the malignant and normal tissues were correlated.
MATERIALS AND METHODS: A total of 23 patients with 14 urinary bladder carcinomas and 9 prostate carcinomas, and 50 healthy controls with normal ultrasonographic urinary bladder and prostate gland imaging findings were enrolled in the study. The ADC values were reported as the mean +/- standard deviation. Student's t test was performed to compare the ADC values of the normal and pathological tissues. Diffusion-weighted imaging (DWI) was performed with b factors of 0, 500, and 1000 s/mm(2), and the ADC values of the normal tissues and lesions were calculated.
RESULTS: The mean ADC value of the urinary bladder wall of the control group and bladder carcinomas were (2.08 +/- 0.22 x 10(-3)mm(2)/s) and (0.94 +/- 0.18 x 10(-3)mm(2)/s), respectively. In addition, the ADC values of the normal peripheral (2.07 +/- 0.33 x 10(-3)mm(2)/s), transitional zones (1.46 +/- 0.23 x 10(-3)mm(2)/s) of the prostate, seminal vesicles (2.13 +/- 0.13 x 10(-3)mm(2)/s) and the prostate carcinomas (1.06 +/- 0.17 x 10(-3)mm(2)/s) were calculated. The comparison of mean ADC values of the peripheral-transitional zones of the prostate, normal bladder wall-bladder carcinomas, and peripheral zone prostate carcinomas were statistically significant (P < 0.01).
CONCLUSION: The present study demonstrated that ADC measurement has a potential ability to differentiate carcinomas from normal bladder wall and prostate gland.

Entities:  

Mesh:

Year:  2009        PMID: 19517380

Source DB:  PubMed          Journal:  Diagn Interv Radiol        ISSN: 1305-3825            Impact factor:   2.630


  7 in total

1.  The value of diffusion-weighted MRI in the diagnosis of malignant and benign urinary bladder lesions.

Authors:  S Avcu; M N Koseoglu; K Ceylan; M D Bulut; M Dbulutand; O Unal
Journal:  Br J Radiol       Date:  2011-01-11       Impact factor: 3.039

2.  Diagnostic performance of diffusion-weighted magnetic resonance imaging in bladder cancer: potential utility of apparent diffusion coefficient values as a biomarker to predict clinical aggressiveness.

Authors:  Shuichiro Kobayashi; Fumitaka Koga; Soichiro Yoshida; Hitoshi Masuda; Chikako Ishii; Hiroshi Tanaka; Yoshinobu Komai; Minato Yokoyama; Kazutaka Saito; Yasuhisa Fujii; Satoru Kawakami; Kazunori Kihara
Journal:  Eur Radiol       Date:  2011-06-18       Impact factor: 5.315

3.  Non-invasive quantification of tumour heterogeneity in water diffusivity to differentiate malignant from benign tissues of urinary bladder: a phase I study.

Authors:  Huyen T Nguyen; Zarine K Shah; Amir Mortazavi; Kamal S Pohar; Lai Wei; Guang Jia; Debra L Zynger; Michael V Knopp
Journal:  Eur Radiol       Date:  2016-08-23       Impact factor: 5.315

4.  Role of diffusion-weighted magnetic resonance imaging in prostate cancer evaluation.

Authors:  D Rinaldi; F Fiocchi; G Ligabue; G Bianchi; P Torricelli
Journal:  Radiol Med       Date:  2012-05-14       Impact factor: 3.469

5.  The role of diffusion weighted magnetic resonance imaging in oncologic settings.

Authors:  Zulkif Bozgeyik; Mehmet Ruhi Onur; Ahmet Kursad Poyraz
Journal:  Quant Imaging Med Surg       Date:  2013-10

Review 6.  Pitfalls and Limitations of Diffusion-Weighted Magnetic Resonance Imaging in the Diagnosis of Urinary Bladder Cancer.

Authors:  Wei-Ching Lin; Jeon-Hor Chen
Journal:  Transl Oncol       Date:  2015-06       Impact factor: 4.243

7.  The Correlation between Diffusion-Weighted Imaging and Histopathological Evaluation of 356 Prostate Biopsy Sites in Patients with Prostatic Diseases.

Authors:  R Kilinç; O G Doluoglu; B Sakman; D S Ciliz; E Yüksel; O Adsan; M Cetinkaya
Journal:  ISRN Urol       Date:  2012-06-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.